There is now a shortage of life-saving drug Tocilizumab not just in Pakistan but across the world

Islamabad, September 05, 2021 (PPI-OT): Tocilizumab, especially in combination with dexamethasone, has been effective at lowering the mortality rate among COVID-19 patients whose respiratory systems decomposed rapidly and required oxygen delivery through a high-flow device or non-invasive ventilation.

However, there is now a shortage of this life-saving drug not just in Pakistan but across the world. Regulatory bodies in various countries have re-directed healthcare providers to alternatives. As per the latest guidelines issued by the Ministry of National Health Services, Regulations and Coordination, baricitinib or tofacitinib are appropriate alternatives to tocilizumab. Both belong to the same class of anti-inflammatory drugs i.e. the Janus kinase (JAK) inhibitors.

Baricitinib (or tofacitinib) should only be given in combination with dexamethasone or another corticosteroid. Healthcare workers, especially those involved in critical care of COVID-19 patients, should visit the NCOC website and review the guidelines which include more details about dosage and precautions.

For more information, contact:
Principal Information Officer,
Press Information Department (PID)
Tel: +92-51-9252323, +92-51-9252324
Fax: +92-51-9252325, +92-51-9252326
Email: piopid@gmail.com
Website: www.pid.gov.pk